Worldwide Clinical Trials

DECEMBER 12, 2022

Genetic testing provides patients with a diagnosis for their illness, helps patients and family members to understand risks of developing new diseases, and can be used to support clinical trial advancement. What are the benefits and limitations to using genetic testing? It is important to consider the type of testing performed (e.g.,

Clinical Trials 130

Clinical Trials Clinical Trials Genetics Trials 130

pharmaphorum

JANUARY 18, 2023

In 2016, scientists behind a study called the Resilience Project analysed genetic data from 589,000+ people and found 13 adults who carried genetic variants that should have resulted in serious – even deadly – childhood disease, but who were apparently healthy. Giving participants something in return.

Genetic Disease 97

Genetic Disease Genetics Research Genome 97

Worldwide Clinical Trials

AUGUST 14, 2024

Historically, these indications have challenged the one-size-fits-all treatment approach due to patient variability, such as genetic differences in drug metabolism and underlying health conditions. This resistance may occur due to genetic mutations, epigenetic changes, or a tumor’s microenvironment.

Genetics 195

Genetics Protein Gene Genotype 195

XTalks

JANUARY 21, 2025

The Shield test provides a non-invasive approach to colorectal cancer screening by analyzing blood for key DNA changes linked to cancer. There, plasma is separated, and tumor DNA is identified by detecting genetic mutations, methylation patterns and fragmentation signals. Photo courtesy of BD.

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

XTalks

SEPTEMBER 28, 2020

Based on the genetic biomarker(s) identified, the most effective therapy targeting the specific molecular marker can be selected. The test involves isolating circulating tumor DNA in the blood and sequencing it to look for relevant gene mutations. In the US, Medicare covers the test.

Gene 105

Gene DNA Life Science Genotype 105

XTalks

FEBRUARY 4, 2021

Through these collaborations, cohort research dataset sharing programs allow for whole-genome sequence and genotype data to be made available for independent research. The project began in 2004, in the early days of biobanking for DNA, says Dr. Bernard, and has grown tremendously since. A Biorepository versus a Bioresource.

Research 98

Research Biobanking Drugs Genomics 98

Bioengineer

JANUARY 16, 2024

Analysis of circulating tumor (ct) DNA at the time of treatment discontinuation or progression showed that 49% of patients in the AURA3 trial lacked the T790M mutation. Another genetic change at the C797 residue in the ATP binding region of EGFR’s exon 20 has emerged as a key mechanism of resistance to osimertinib.

Genomics 119

Genomics Genome Protein In-Vitro 119